Core Viewpoint - Equasens Group reported a revenue of €57.0 million for Q1 2025, reflecting a growth of 6.9% on a reported basis and 5.9% like-for-like compared to Q1 2024 [3][4]. Revenue Breakdown - The Pharmagest Division generated €42.0 million in revenue, marking a 5.5% increase on a reported basis [6][7]. - The Axigate Link Division reported revenue of €8.3 million, also up 5.5% on both reported and like-for-like bases [10][8]. - The e-Connect Division saw significant growth, with revenue reaching €3.5 million, up 21.2% on a reported and like-for-like basis [10][9]. - The Medical Solutions Division reported revenue of €2.7 million, a 25.1% increase on a reported basis, driven by the integration of CALIMED [10][11]. - The Fintech Division experienced a decline in revenue to €0.6 million, down 8.3% on both reported and like-for-like bases due to a restructuring of the customer base [21]. Business Type Performance - Sales of configurations and hardware increased by 7.7%, with Pharmagest and e-Connect showing strong growth [6][10]. - Scalable maintenance and professional training services grew by 3.5%, indicating customer loyalty [6][10]. - Software solutions and subscriptions rose by 11.3%, supported by acquisitions and organic growth [6][10]. Market Insights - The French market showed positive signals, with all business lines reporting growth, particularly in equipment sales [10]. - The Nursing Home sector benefited from public funding, while the Homecare sector maintained a promising level of new business [10]. - Revenue growth was also observed in Italy (up 13.3%), Belgium (up 4.8%), and Germany (up 12.5%) [10]. Future Outlook - The company is optimistic about growth in Q2 2025, supported by a strong order level in the Pharmacy sector [13]. - Equasens Group remains focused on external growth opportunities in France and Europe to strengthen its position in digital healthcare solutions [14].
Equasens: Q1 revenue at 31 March 2025